- Expediting: Fast track, Breakthrough therapy, Accelerated approval, Priority review, RMAT
- Key considerations: Clinical evidence, surrogate endpoints, post-approval requirements
- Major health policy concerns around support for developing new oncology drugs
- Cost, access, regulation, public funding, balancing innovation with long-term care
